Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parexel Says It Is Ideally Positioned As Big Pharma Shakes Up R&D Efforts

This article was originally published in The Pink Sheet Daily

Executive Summary

Noting its recent five-year contract with Pfizer, the CRO predicts 13% revenue growth for fiscal 2012.

You may also be interested in...



Parexel Outlines Biopharma Advances And Increased Outsourcing

The CRO highlighted industry R&D success and an ever-expanding reliance on outsourcing at its June 26 investor day. Management said there are already more clinical development staff at CROs than within biopharma and suggested that soon more drug development will be done by CROs than drug manufacturers.

In Private Equity Hands, PPD Could Seek More Deals

Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.

In Private Equity Hands, PPD Could Seek More Deals

Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel